Ortho Tri-Cyclen tablets, marketed by Janssen Pharmaceuticals Inc., had annual sales of $488 million in the US.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced the launch of a generic equivalent of Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets in the US. Teva’s Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets, USP) is an oral contraceptive, available in a 28-day blister pack dispenser, used by women to prevent pregnancy.
Ortho Tri-Cyclen tablets, marketed by Janssen Pharmaceuticals Inc., had annual sales of $488 million in the US, according to IMS data as of October 2015.
Published by Globes [online], Israel business news - www.globes-online.com - on January 5, 2016
© Copyright of Globes Publisher Itonut (1983) Ltd. 2016
Teva